Suuqa Daaweynta Cudurrada Huntington cabbirka ayaa lagu qiimeeyay USD 325 milyan sanadka 2021, si ay u USD 1813.18 milyan marka la gaaro 2030, soo bandhigaya a CAGR ee 19.5% inta u dhaxaysa 2022-2030.
Inta lagu jiro xilliga saadaasha, qaybta ugu dhaqsaha badan ee u koraysa ee suuqa daweynta wax ka beddelka ayaa la filayaa inay noqoto midda leh kobaca ugu sarreeya. Tan waxa u sabab ah kor u kaca R&D ee daaweynta wax ka beddelka cudurada iyo kor u kaca baahida alaabooyinka horumarsan sida daaweynta hidda-wadaha ama daawaynta unugyada stem. Mustaqbalka, suuqa waxa laga yaabaa in lagu shido hindisayaal dawladeed oo wanaagsan sida Fast Track Designation (US FDA), kaas oo dedejiya habka diiwaangelinta. Dawada Sage Therapeutics's SAGE-718 waxaa si degdeg ah u siisay FDA US Sebtembar 2021 sida daawaynta suurtagalka ah ee Cudurka Huntington.
Waxaad codsan kartaa nooca demo ee warbixinta ka hor intaadan iibsan halkan: https://market.us/report/huntington-s-disease-treatment-market/request-sample/
Suuqa Daaweynta Cudurrada Huntington: Darawaliinta
Kordhinta qaadashada daawaynta la xoojiyey iyo dawooyinka si loogu kaxeeyo baahida daawaynta ee Ikhtiyaarka.
Ballaarinta suuqa waxaa dhaqaajin doona ka-qaybgalka ciyaartoyga warshadaha muhiimka ah ee raadinta daawaynta Huntington's Disease (HD). Tani waxay sabab u noqon kartaa tirada bukaanka oo sii kordheysa iyo faafitaanka cudurrada ee Yurub iyo Waqooyiga Ameerika. Kobaca suuqa waxa caawin doona baahida aan la daboolin ee dawooyinka wax ka beddelka HD iyo daawaynta.
Kordhinta Cilmi-baarista iyo Horumarinta si loo Dar-dargeliyo Horumarinta Suuqa.
Cudurka Huntington waa mid aan laga bogsan karin. Ma jirto wax daawayn ama daawo ah. Tani waxay ka dhigan tahay in ay jiraan fursado badan oo lagu baaro laguna horumariyo doorashooyin daweyn oo cusub. Tani waxay u badan tahay inay kor u qaadi doonto kobaca suuqa si weyn xilliga saadaasha. Barnaamijyada suurtagalka ah ee dawladda ee kor u qaadaya horumarinta dawooyinka cusub waxay noqon doontaa arrin kale oo horseedda ballaarinta suuqa.
Suuqa Daaweynta Cudurrada Huntington: Xannibaadyada
Daroogo yaraantu waxay caqabad ku noqotaa kobaca suuqa.
Cudurka Huntington waxa uu leeyahay tiro xaddidan oo dawooyin shati ah sababtoo ah heerarka adag iyo xannibaadaha. Tani waxay u badan tahay inay xaddiddo kobaca suuqa inta lagu jiro xilliga saadaasha oo dhan. Sababo la xiriira dhaleeceynta la xiriirta cudurka Huntington, wacyiga hooseeya ee meelo badan oo adduunka ah, xannibaadaha oggolaanshaha adag ee daroogada, qorshooyinka daaweynta beddelka ah, iyo tiro yar oo dawooyin la oggolaaday waxay u badan tahay inay xaddidaan kobaca suuqa.
Isbeddellada Furaha Suuqa:
Suuqa Daaweynta Cudurrada Huntington waxaa la saadaalinayaa in ay saami weyn ku yeelan doonto qaybta daawaynta Calaamadaha.
Qaybta ugu badan ayaa la filayaa in ay hayso qaybta daawaynta calaamadaha inta lagu jiro sanadka saadaasha. Dakhliga qaybta waxa lagu kordhiyey helista xad sare oo aad u saraysa iyo heerka isticmaalka daaweynta maaraynta calaamadaha. Qaybtani waxay soo saartaa dakhli sare sababtoo ah baahida daawaynta badan iyo faragelinta koox khaas ah.
Naafonimada mootooyinka iyo chorea ayaa ah diiradda ugu weyn ee horumarinta daaweynta calaamadaha. Chorea ayaa weli ah sifada ugu caansan ee cudurka Huntington. Inta badan daraasado daweyn ayaa lagu sameeyay. Neurocrine Biosciences, tusaale ahaan, waxay ku dhawaaqday in valentine ay si weyn hoos ugu dhigtay chorea ee bukaanada Huntington ee Wajiga 3 ee tijaabada kiliinikada ee loo yaqaan-KINECT HD bishii Diseembar 2021. Warqad cilmi baaris ah oo May 2021 lagu daabacay Maskaxda ayaa muujisay in daaweynta hidde-sidaha ay hoos u dhigi karto horumarka calaamadaha. Daraasadahan socda ayaa door muhiim ah ka ciyaari doona go'aaminta saamiga suuqa ee qaybtan sanadaha soo socda.
Horumarkii dhawaa:
Ionis Pharmaceuticals, Inc. ayaa ku dhawaaqay Janaayo 2022 iskaashi lala yeesho Roche si loo qiimeeyo tominersen ee tijaabada Wajiga 2 ee daaweynta Cudurka Huntington.
Novartis, oo ah hormuudka soo saaraha daaweynta cudurada wax ka beddelka ee cudurka Huntington, ayaa ku dhawaaqay in Novartis la siiyay heerka FDA Fast Track Diseembar 2021.
Muuqaalka Tartanka:
- Daawooyinka Valeant
- Teva Pharmaceuticals
- Sayniska Nolosha Wave
- Ionis Pharmaceuticals/ Roche
- Raptor Pharmaceuticals
- Prana Biotechnology
nooca
- Daawaynta Calaamadaha
- Daaweynta Cudur-isbeddelka
Codsiga
- Hospitals
- Xarumaha Qalliinka Ambulatory
Warshadaha, By Gobolka
- Aasiya-Baasifiga [Shiinaha, Koonfur-bari Aasiya, Hindiya, Japan, Kuuriya, Galbeedka Aasiya]
- Yurub [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- Waqooyiga Ameerika [Mareykanka, Kanada, Mexico]
- Bariga Dhexe & Afrika [GCC, Waqooyiga Afrika, Koonfur Afrika]
- Koonfurta Ameerika [Brazil, Argentina, Columbia, Chile, Peru]
Su'aalaha muhiimka ah:
- Waa maxay xajmiga suuqa ee daaweynta cudurka Huntington ee ku koraya?
- Waa kuwee ka qaybqaatayaasha ugu waaweyn ee suuqa daawaynta cudurka Huntington?
- Waa maxay qiimaha suuqa ee la filayo in lagu daweeyo cudurka Huntington sanadka 2031?
- Aaggee ka dhigay maal-gelinta ugu badan ee suuqa lagu daweynayo cudurka Huntington?
- Waa kuwee ka qaybqaatayaasha ugu waaweyn ee suuqa daawaynta cudurka Huntington?
- Waa maxay doorsoomayaasha saamaynta ku leh suuqa daawaynta cudurka Huntington?
- Waa maxay CAGR ee suuqa daawaynta cudurka Huntington koray intii u dhaxaysay 2015 iyo 2021?
- Waa maxay isbeddellada ugu waaweyn ee baahida macaamiisha marka dhaqaaluhu is beddelo?
- Waa maxay dhibaatooyinka ay SMEs iyo alaab-qeybiyeyaal caan ah ay kala kulmaan suuqa daaweynta cudurka Huntington?
Warbixino badan oo laxidhiidha oo ka socda Mareegaha Market.us:
Baaxadda Suuqa Daaweynta Cudurka Sickle-Cell ee Caalamiga ah qiimo lahaa USD 1.9 Bilyan sanadka 2021 waxaana la saadaalinayaa inuu la kulmi doono a 17.9% CAGR inta lagu jiro 2023-2032.
Suuqa Daaweynta Xanuunka Raaga ee Caalamiga ah waxaa la saadaalinayaa in lagu gaaro qiimeynta USD 173.53 Bn marka la gaaro 2031 CAGR oo ah 7.2%, ka USD 86.58 Bn sanadka 2021.
Suuqa Daaweynta Burooyinka xubinta taranka waxaa la saadaalinayaa in la gaaro qiimeyn $2.16 Billion marka la gaaro 2032 CAGR oo ah 4.8%, ka USD 1.63 Billion in 2021.
Suuqa Daawaynta Nabarrada Caalamiga ah waxaa la saadaalinayaa in la gaaro qiimeyn USD 82.59 Bn sanadka 2032 ka a CAGR of 13.85%, ka USD 27.32 Bn in 2022.
Suuqa daawaynta acromegaly ee caalamiga ah lagu qiimeeyay at USD 1,497 milyan sanadka 2021. Waxaa la saadaalinayaa inuu koro 7.55% muddada saadaasha.
Ku saabsan Suuqa.us
Market.US (Powered by Prudour Private Limited) waxay ku takhasustay cilmi baarista qoto dheer ee suuqa iyo falanqaynta waxayna caddaynaysay awooddeeda shirkad la-talin iyo cilmi-baaris suuqeed oo habaysan, marka laga reebo inay tahay warbixin cilmi-baaris suuqeed oo aad loo raadsaday oo siisay shirkad.
Faahfaahin Xidhiidh
Kooxda Horumarinta Ganacsiga Caalamiga ah - Market.us
Cinwaanka: 420 Lexington Avenue, Suite 300 New York City, NY 10170, Mareykanka
Telefoon: +1 718 618 4351 (Caalami), Telefoon: +91 78878 22626 (Aasiya)
E-mail: [emailka waa la ilaaliyay]
MAXAA LAGU QAADAYAA MAQAALKAN:
- Over the forecast period, the fastest growing segment in the disease-modifying therapies market is expected to be the one with the highest growth.
- announced in January 2022 a partnership with Roche to evaluate tominersen in a Phase 2 trial for Huntington’s Disease treatment.
- Due to the stigma associated with Huntington's disease, low awareness in many parts of the world, strict drug approval restrictions, alternative therapies plans, and a small number of approved drugs will likely limit the market growth.
